Novo Nordisk A/S (NYSE:NVO) Shares Down 5.2% - What's Next?

Novo Nordisk A/S (NYSE:NVO - Get Free Report)'s share price fell 5.2% on Monday . The company traded as low as $78.17 and last traded at $78.74. 21,239,835 shares changed hands during mid-day trading, an increase of 159% from the average session volume of 8,206,201 shares. The stock had previously closed at $83.07.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on NVO. Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Finally, BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Buy" and an average price target of $140.20.

Novo Nordisk A/S Stock Performance

The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $353.33 billion, a price-to-earnings ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The stock's fifty day simple moving average is $97.76 and its 200-day simple moving average is $116.89.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds have recently bought and sold shares of the stock. Strategic Investment Solutions Inc. IL acquired a new stake in Novo Nordisk A/S in the second quarter valued at approximately $25,000. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S during the third quarter worth $42,000. Albion Financial Group UT raised its position in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after acquiring an additional 278 shares in the last quarter. Finally, Carolina Wealth Advisors LLC purchased a new stake in Novo Nordisk A/S during the third quarter worth approximately $48,000. Institutional investors and hedge funds own 11.54% of the company's stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.